Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats

Kiley S. Ariail, Bruce F. Bebo, Kirsten Adlard, Ian Robey, Gregory Burrows, Mark J. Newman, Charles W. Todd, Arthur Vandenbark, Halina Offner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment of human autoimmune diseases may be enhanced by using adjuvants that can selectively induce immunoregulatory responses. Two versions of a novel nonionic block copolymer adjuvant suitable for human use, Optivax Oil Formulation (OF) and Optivax Aqueous Formulation (AF), were evaluated for induction of immunity to encephalitogenic and regulatory T-cell receptor (TCR) V-gene determinants. In Lewis rats immunized with myelin basic protein (BP), Optivax OF was more efficient than Optivax AF for inducing delayed type hypersensitivity (DTH), T-cell proliferation, antibodies, and even mild clinical signs of experimental autoimmune encephalomyelitis (EAE). Similarly, Optivax OF was more efficient for inducing inflammatory T-cell and antibody responses to immunoregulatory Vβ8.2 proteins and peptides than Optivax AF, which induced a noninflammatory Th2 response. In general, DTH response to the various immunogens was reflected by increased cellularity and mRNA levels for IFN-γ in draining lymph nodes, whereas LN cell proliferation without DTH was characterized by increased IL-2 mRNA levels but low or absent IFN-γ message. These data suggest important differential adjuvant effects of Optivax OF versus Optivax AF on the respective induction of Th1 versus Th2 responses that may be useful in the selective treatment of human immune disorders.

Original languageEnglish (US)
Pages (from-to)99-108
Number of pages10
JournalVaccine
Volume16
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

adjuvants
Antibody Formation
delayed hypersensitivity
Oils
Delayed Hypersensitivity
T-lymphocytes
T-Lymphocytes
oils
antibodies
rats
cell proliferation
water
Cell Proliferation
T-Cell Receptor Genes
Messenger RNA
Myelin Basic Protein
composite polymers
Autoimmune Experimental Encephalomyelitis
autoimmune diseases
Immune System Diseases

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats. / Ariail, Kiley S.; Bebo, Bruce F.; Adlard, Kirsten; Robey, Ian; Burrows, Gregory; Newman, Mark J.; Todd, Charles W.; Vandenbark, Arthur; Offner, Halina.

In: Vaccine, Vol. 16, No. 1, 01.01.1998, p. 99-108.

Research output: Contribution to journalArticle

Ariail, Kiley S. ; Bebo, Bruce F. ; Adlard, Kirsten ; Robey, Ian ; Burrows, Gregory ; Newman, Mark J. ; Todd, Charles W. ; Vandenbark, Arthur ; Offner, Halina. / Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats. In: Vaccine. 1998 ; Vol. 16, No. 1. pp. 99-108.
@article{dabfc0332cd14bcbb8bbbb6bf805fdfe,
title = "Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats",
abstract = "Treatment of human autoimmune diseases may be enhanced by using adjuvants that can selectively induce immunoregulatory responses. Two versions of a novel nonionic block copolymer adjuvant suitable for human use, Optivax Oil Formulation (OF) and Optivax Aqueous Formulation (AF), were evaluated for induction of immunity to encephalitogenic and regulatory T-cell receptor (TCR) V-gene determinants. In Lewis rats immunized with myelin basic protein (BP), Optivax OF was more efficient than Optivax AF for inducing delayed type hypersensitivity (DTH), T-cell proliferation, antibodies, and even mild clinical signs of experimental autoimmune encephalomyelitis (EAE). Similarly, Optivax OF was more efficient for inducing inflammatory T-cell and antibody responses to immunoregulatory Vβ8.2 proteins and peptides than Optivax AF, which induced a noninflammatory Th2 response. In general, DTH response to the various immunogens was reflected by increased cellularity and mRNA levels for IFN-γ in draining lymph nodes, whereas LN cell proliferation without DTH was characterized by increased IL-2 mRNA levels but low or absent IFN-γ message. These data suggest important differential adjuvant effects of Optivax OF versus Optivax AF on the respective induction of Th1 versus Th2 responses that may be useful in the selective treatment of human immune disorders.",
author = "Ariail, {Kiley S.} and Bebo, {Bruce F.} and Kirsten Adlard and Ian Robey and Gregory Burrows and Newman, {Mark J.} and Todd, {Charles W.} and Arthur Vandenbark and Halina Offner",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0264-410X(97)00150-3",
language = "English (US)",
volume = "16",
pages = "99--108",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Novel adjuvants for induction of T-cell and antibody responses to encephalitogenic and regulatory determinants in Lewis rats

AU - Ariail, Kiley S.

AU - Bebo, Bruce F.

AU - Adlard, Kirsten

AU - Robey, Ian

AU - Burrows, Gregory

AU - Newman, Mark J.

AU - Todd, Charles W.

AU - Vandenbark, Arthur

AU - Offner, Halina

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Treatment of human autoimmune diseases may be enhanced by using adjuvants that can selectively induce immunoregulatory responses. Two versions of a novel nonionic block copolymer adjuvant suitable for human use, Optivax Oil Formulation (OF) and Optivax Aqueous Formulation (AF), were evaluated for induction of immunity to encephalitogenic and regulatory T-cell receptor (TCR) V-gene determinants. In Lewis rats immunized with myelin basic protein (BP), Optivax OF was more efficient than Optivax AF for inducing delayed type hypersensitivity (DTH), T-cell proliferation, antibodies, and even mild clinical signs of experimental autoimmune encephalomyelitis (EAE). Similarly, Optivax OF was more efficient for inducing inflammatory T-cell and antibody responses to immunoregulatory Vβ8.2 proteins and peptides than Optivax AF, which induced a noninflammatory Th2 response. In general, DTH response to the various immunogens was reflected by increased cellularity and mRNA levels for IFN-γ in draining lymph nodes, whereas LN cell proliferation without DTH was characterized by increased IL-2 mRNA levels but low or absent IFN-γ message. These data suggest important differential adjuvant effects of Optivax OF versus Optivax AF on the respective induction of Th1 versus Th2 responses that may be useful in the selective treatment of human immune disorders.

AB - Treatment of human autoimmune diseases may be enhanced by using adjuvants that can selectively induce immunoregulatory responses. Two versions of a novel nonionic block copolymer adjuvant suitable for human use, Optivax Oil Formulation (OF) and Optivax Aqueous Formulation (AF), were evaluated for induction of immunity to encephalitogenic and regulatory T-cell receptor (TCR) V-gene determinants. In Lewis rats immunized with myelin basic protein (BP), Optivax OF was more efficient than Optivax AF for inducing delayed type hypersensitivity (DTH), T-cell proliferation, antibodies, and even mild clinical signs of experimental autoimmune encephalomyelitis (EAE). Similarly, Optivax OF was more efficient for inducing inflammatory T-cell and antibody responses to immunoregulatory Vβ8.2 proteins and peptides than Optivax AF, which induced a noninflammatory Th2 response. In general, DTH response to the various immunogens was reflected by increased cellularity and mRNA levels for IFN-γ in draining lymph nodes, whereas LN cell proliferation without DTH was characterized by increased IL-2 mRNA levels but low or absent IFN-γ message. These data suggest important differential adjuvant effects of Optivax OF versus Optivax AF on the respective induction of Th1 versus Th2 responses that may be useful in the selective treatment of human immune disorders.

UR - http://www.scopus.com/inward/record.url?scp=0031986362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031986362&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(97)00150-3

DO - 10.1016/S0264-410X(97)00150-3

M3 - Article

C2 - 9607016

AN - SCOPUS:0031986362

VL - 16

SP - 99

EP - 108

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -